Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Liabilities (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $18.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 916.02% year-over-year to $18.5 million, compared with a TTM value of $18.5 million through Dec 2025, up 916.02%, and an annual FY2025 reading of $18.5 million, up 916.02% over the prior year.
  • Other Non-Current Liabilities was $18.5 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $14.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $18.5 million in Q4 2025 and bottomed at $260000.0 in Q2 2022.
  • Average Other Non-Current Liabilities over 5 years is $3.5 million, with a median of $1.9 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities crashed 77.21% in 2022, then surged 916.02% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $270000.0 in 2021, then surged by 581.11% to $1.8 million in 2022, then rose by 1.03% to $1.9 million in 2023, then fell by 1.88% to $1.8 million in 2024, then soared by 916.02% to $18.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for KNSA at $18.5 million in Q4 2025, $14.5 million in Q3 2025, and $9.3 million in Q2 2025.